Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design

Marco Valgimigli, Gianluca Campo, Nicoletta De Cesare, Pascal Vranckx, Martial Hamon, Dominick J. Angiolillo, Manel Sabatè, Fabrizio Ferrari, Alessandro Furgieri, Carlo Tumscitz, Alessandra Repetto, Salvatore Colangelo, Emanuele Meliga, Moh'd Kubbajeh, Giovanni Parrinello, Gianfranco Percoco, Roberto Ferrari

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods: We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion: The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume22
Issue number4
DOIs
Publication statusPublished - Aug 2008

Keywords

  • Aspirin resistance
  • Clopidogrel resistance
  • Platelet inhibition
  • Tirofiban

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design'. Together they form a unique fingerprint.

Cite this